Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prasaprohyai is a traditional Thai polyherbal formula primarily composed of *Kaempferia galanga* (sand ginger) along with nine other botanical ingredients. It is traditionally utilized in Thai medicine for the treatment of respiratory ailments and fever. Modern clinical development, led by Thammasat University, has focused on a 95% ethanolic extract of the formula for the treatment of allergic rhinitis. The extract contains bioactive compounds like ethyl-p-methoxycinnamate, which demonstrate potent anti-inflammatory and anti-allergic properties by inhibiting mast cell degranulation and reducing the production of pro-inflammatory cytokines. A Phase I clinical trial has been conducted to evaluate the safety and tolerability of 100 mg and 200 mg doses in healthy volunteers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prasaprohyai.